Viatris Inc
(HAM:VIA)
€
12.47
0 (0%)
Market Cap: 14.94 Bil
Enterprise Value: 28.20 Bil
PE Ratio: 0
PB Ratio: 0.80
GF Score: 65/100 Viatris Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023 / 08:20PM GMT
Release Date Price:
€8.69
(+0.02%)
Nathan Allen Rich
Goldman Sachs Group, Inc., Research Division - Research Analyst
Great. Well, good afternoon, everyone. Thanks so much for joining us for our first afternoon session. My name is Nathan Rich, I cover the generic pharma space for Goldman Sachs. Very pleased to have Viatris up here with us. I'll do some quick introductions and then we can jump into the Q&A.
So to my right, Scott Smith, new Chief Executive Officer; in the center, Rajiv Malik, President; and Sanjeev Narula, CFO. So thank you guys for joining us. Really appreciate you being here.
Scott Andrew Smith
Viatris Inc. - CEO & Director
Thank you.
Questions & Answers
Nathan Allen Rich;Scott Andrew Smith
Goldman Sachs Group, Inc., Research Division - Research Analyst;
Great. Well, Scott, new to the company. So you joined the Board in December, became CEO in April. Can you maybe just talk about what attracted you to Viatris and what your initial impressions of the company has been so far?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot